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Background: Akt and its downstream signalling pathways contribute to the aetiology and progression of colorectal carcinoma
(CRC). Targeting the Akt pathway is an attractive strategy but few chemotherapeutic drugs have been used to treat CRC with only
limited success. BI-69A11, a small molecule inhibitor of Akt, efficiently inhibits growth in melanoma cells. Melanoma differentiation
associated gene-7 (mda-7)/interleukin-24 promotes cancer-selective apoptosis when delivered by a tropism-modified replication
incompetent adenovirus (Ad.5/3-mda-7). However, Ad.5/3-mda-7 displays diminished antitumour efficacy in several CRC cell lines,
which correlates with the expression of K-RAS.
Methods: The individual and combinatorial effect of BI-69A11 and Ad.5/3-mda-7 in vitro was studied by cell viability, cell cycle,
apoptosis and invasion assays in HT29 and HCT116 cells containing wild type or mutant K-ras, respectively. In vivo HT29 tumour
xenografts were used to test the efficacy of the combination treatment.
Results: BI-69A11 inhibited growth and induced apoptosis in CRC. However, combinatorial treatment was more effective
compared with single treatment. This combination showed profound antitumour and anti angiogenic effects in vitro and in vivo by
downregulating Akt activity.
Conclusions: BI-69A11 enhances the antitumour efficacy of Ad.5/3-mda-7 on CRC overexpressing K-RAS by inducing apoptosis
and regulating Akt activity thereby warranting further evaluation in treating CRC.
The phosphoinositide 3-kinase (PI3K)–Akt pathway has received
significant attention in human tumourigenesis because it regulates
multiple cellular activities including cell cycle, proliferation,
growth, apoptosis, autophagy and protein synthesis (Bellacosa
et al, 2005). The Akt super family consists of three members,
AKT1, AKT2 and AKT3, that are composed of a conserved
N-terminal pleckstrin homology (PH) domain, a central catalytic
domain and a C-terminal regulatory hydrophobic motif (Vivanco
and Sawyers, 2002; Hanada et al, 2004). Akt, a serine/threonine
kinase, is one of the downstream targets of PI3K. Akt is activated
owing to the formation of phosphatidylinositol (3, 4, 5)-tripho-
sphate (PIP3) by PI3K. Phosphatidylinositol (3, 4, 5)-triphosphate
binds with the PH domains of Akt and aids in the recruitment of
Akt to the plasma membrane, which alters the conformation of Akt
to allow for subsequent phosphorylation by phosphoinositide-
dependent kinase-1 (PDK1) (Vivanco and Sawyers, 2002). Akt is
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activated through the phosphorylation of Thr308, but phosphor-
ylation of the Ser473 residue located at the hydrophobic
C-terminal region is also required for full activation of the kinase
(Pal and Mandal, 2012). However, kinases have been identified that
assist in this activation that are members of the mammalian target
of rapamycin complex 2 and DNA-dependent protein kinase
family (Cantley, 2002).
Loss or mutation of the tumour suppressor phosphatase and
tensin homologue (PTEN), mutation/overexpression of PI3K,
activation or mutation of growth factor receptors and oncogenes,
have been attributed to the alteration of the PI3K–Akt pathway in
tumours of the colon, breast, brain, prostate, stomach and many
other organs (Samuels and Waldman, 2010). Akt overexpression is
associated with 57% sporadic colon tumours, which is higher than
that in many other cancers. Moreover, activation of Akt was
observed in colon cancer cells, but not in normal mucosa. Recently,
amplification of Akt was found to be owing to an activating
mutation in the PH domain of AKT1 (E17K) in melanoma, breast,
colorectal and ovarian cancers (Miyaki et al, 2007; Nosho et al,
2008). Akt represents a potential target for cancer therapeutics
owing to its association with resistance towards radiotherapy and
chemotherapy (Bussink et al, 2008; Huang and Hung, 2009).
BI-69A11, an imidazole derivative, is a competitive Akt
inhibitor. Previous studies suggest that BI-69A11 is more effective
in inhibiting Akt and eliciting cell death in melanoma cells
exhibiting elevated Akt activity (Gaitonde et al, 2009). BI-69A11
also causes dephosphorylation of Akt at Ser473, which disables
Akt-HSP-90. This association prevents ubiquitin-mediated degra-
dation of Akt. Recent studies also suggest that antitumour efficacy
of BI-69A11 results from both the inhibition of the NF-kB pathway
and the previously demonstrated inhibition of Akt (Feng et al,
2011; Barile et al, 2013).
Melanoma differentiation associated gene-7/interleukin-24
(mda-7/IL-24), an IL-10 family cytokine exhibits ubiquitous anti-
cancer activity owing to its unique ‘bystander’ antitumour
properties, which causes induction of apoptosis and growth
inhibition in a wide array of human cancers (Dash et al, 2010).
In contrast, mda-7/IL-24 shows no apparent toxicity and marginal
growth inhibitory effects in normal cells (Fisher, 2005; Lebedeva
et al, 2005; Gupta et al, 2006a, b). Experiments confirm that
interactions with the endoplasmic reticulum chaperone BiP/GRP78
are critical for mda-7/IL-24 to induce apoptosis (Gupta et al,
2006a, b). Interestingly, expression of BiP/GRP78 is relatively
higher in colon carcinoma than normal colonic tissue and colon
adenoma (Langer et al, 2008; Xing et al, 2011). Additionally, mda-
7/IL-24 also abrogates cell cycle and induces apoptosis in colon
cancer cell lines through an Akt-dependent pathway. Here we
hypothesised that BI-69A11, a novel Akt inhibitor, would induce
apoptosis of colon cancer cells by downregulating Akt that in turn
would activate BAX and caspase-3 to induce apoptosis. BiP/GRP78
is overexpressed in colon cancer (Chang et al, 2012) and earlier
studies showed that regulation of expression occurs through an
Akt-dependent pathway (Dai et al, 2010; Gray et al, 2013). In
present study, we demonstrate that the combination of BI-69A11
and Ad.5/3-mda-7 (a tropism-modified replication incompetent
adenovirus expressing MDA-7/IL-24) enhances apoptosis through
an Akt-dependent pathway. This data suggests possible applica-
tions of the combination of mda-7/IL-24 and Akt inhibition as a
potential therapeutic strategy for colon cancer.
MATERIALS AND METHODS
Cell lines. Human colon cancer cell lines, HT29 and HCT15 cells
were obtained from the National Centre for Cell Science
(Pune, India) and cultured as recommended by the supplier.
Two additional colorectal carcinoma (CRC) cells HCT116 and
SW480 were a kind gift from Dr Sushanta Roy Chowdhury (IICB,
Kolkata, India). Cells were incubated at 37 1C in a 5% CO2
atmosphere, 95% humidity in RPMI1640 (Gibco-BRL, Rockville,
MD, USA) and McCoy-5A (Gibco-BRL) media supplemented with
10% heat inactivated FBS (Gibco-BRL).
Reagents. Stock solutions of 10mM BI-69A11 (Langer et al, 2008;
Xing et al, 2011), were dissolved in DMSO, stored at  20 1C, and
diluted in fresh medium just before use. Tropism-modified
adenovirus expressing mda-7 or empty vectors were described
previously (Langer et al, 2008; Xing et al, 2011). For Western
blotting analysis, the following antibodies were used: rabbit
monoclonal anti-PARP, anti-XIAP, anti-AIF and anti-Bax, anti-
Caspase-3 (Cell Signaling Technology, Beverly, MA, USA), mouse
monoclonal anti-pro-caspase-3 (BD Pharmingen, NJ, USA), mouse
monoclonal anti-b-actin (Sigma-Aldrich, St Louis, MO, USA), and
horseradish peroxidase-conjugated goat anti-rabbit IgG, goat
anti-mouse IgG (Santa Cruz Biotechnology, Santa Cruz, CA, USA).
Chemiluminescent peroxidase substrate, Propidium iodide,
RNaseA and MTT reagents were purchased from Sigma-Aldrich.
Cell viability assays. Cell proliferation was determined by MTT
assay as described previously (Sarkar et al, 2011). Briefly, 5000 cells
per well were seeded in 96-well plate and treated with different
concentrations of BI-69A11 (0.1–10 mM) and MTT assays were
performed at various time points. For combination studies, cells
were first infected with Ad.5/3-vec or Ad.5/3-mda-7 for 6 h
followed by treatment with/without varying concentrations of
BI-69A11 (0–5 mM) for 48 h.
Cell cycle analysis. The cells were grown and treated with
BI-69A11 for varying time points. Cells were fixed with 70%
ethanol, treated with RNaseA (100mgml 1) and propidium iodide
at a final concentration of 40 mgml 1, and incubated for 45min at
37 1C. Finally, the cells were analysed with the FACS Vantage SE
(BD Corporation, Franklin Lakes, NJ, USA). Cell cycle was also
analysed by using Annexin-FITC apoptosis detection kit (Sigma-
Aldrich) as per manufacturer’s protocol. Cell Quest software
version 2.0 (BD) was used for data analysis.
Morphological studies. After 24 h seeding on a coverslip, cells
were treated with BI-69A11 for 12 and 24 h. Fixed (3.7%
paraformaldehyde) cells were stained with DAPI as per manufac-
turer’s instructions. To see the changes associated with apoptosis,
cells were stained with calcein AM and ethidium homodimer-1
using the LIVE/DEAD Viability/Cytotoxicity kit (Life Technolo-
gies, Carlsbad, CA, USA) as per the manufacturer’s instructions.
Cells were analysed by confocal laser scanning microscopy
(Olympus FluoView FV1000, Version 1.7.1.0, Shinjuku, Tokyo,
Japan) and images were captured, digitised using FLUOVIEW 1000
(Version 1.2.4.0) imaging software (Olympus, Tokyo, Japan).
TUNEL assay. Terminal deoxynucleotidyl transferase dUTP nick
end labelling (TUNEL) assays were performed using the ApopTag
Peroxidase in situ Apoptosis Detection Kit (Promega, Madison,
WI, USA) according to the instructions of the manufacturer.
Propidium iodide was used as a counterstain. Cells were analysed
by confocal laser scanning microscopy at 20 magnification.
Akt kinase assay. To study the kinase activity of Akt, an Akt
kinase Assay was carried out as per the manufacturer’s protocol
(Cell Signaling Technology) (Mandal et al, 2005). The incorpora-
tion of phosphate into glycogen synthase kinase 3 was assessed by
Western blotting analysis with an anti-phospho-specific GSK-3a/b
(Ser21/9) antibody. To assess the level of expression of GSK,
parallel total cell lysates were analysed by Western blotting.
Treatment with insulin growth factor (IGF) to study phospho-
rylation. Cells were seeded in cell culture plates and incubated in
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10% FBS medium overnight. The next day, the cells were washed
and incubated in serum-free medium for 24 h. The experimental
and the control plates were treated with 5 mM of BI-69A11 and with
0.1% DMSO, respectively for 1 h. Cells were then activated with
recombinant human IGF (100 ngml 1) for 30min, washed with
PBS, and scraped with lysis buffer, Western blot was carried out as
described below.
Protein isolation and Western blotting. The HT29 and HCT116
cells were grown and treated with IC50 value of BI-69A11 for 12, 24
and 48 h, respectively, or with control treatment (0.1% DMSO) in
cell culture dishes for 48 h. The cells were then scraped and lysed in
NP-40 lysis buffer (Sigma-Aldrich) and Western Blotting was done
with appropriate primary and secondary antibodies as previously
described (Rajput et al, 2013).
Wound-healing assay. HT29 and HCT116 cell monolayer’s
grown to confluence on six-well plates were wounded by scratching
with a pipette tip and then cultured in the presence or absence of
BI-69A11 (oIC50) for different time points. The wounds were
photographed at 4 and healing was quantified by measuring the
distance between the edges using Adobe Photoshop (Adobe
Systems Inc, San Jose, CA, USA).
Boyden chamber invasion assay. Cell invasion was performed in
a modified Boyden chamber (BD Bioscience, San Diego, CA, USA)
as described previously (Sarkar et al, 2008), according to the
manufacturer’s instructions. The results are expressed as the per
cent of migrated cells as compared with the control (untreated
cells).
Chick chorioallantoic membrane (CAM) assay. To determine
in vivo anti-angiogenic activity, CAM assays were performed as
described previously (Ribatti et al, 2006). Fertilised chicken eggs
were allowed to grow for 9 days in an egg incubator. A 1-cm2
window was created in the eggshell. The shell membrane was
removed to expose the CAM. Conditioned media was implanted
on the CAM. After incubation for 72 h, the upper eggshell was
removed and the neovascular zones were photographed (Sarkar
et al, 2010) and quantified by Volocity software Version 5.4.2.
(Perkin Elmer, Waltham, MA, USA).
HUVEC cell assay. HUVEC cells were seeded at a density of
15 000 cells per well on the polymerised Matrigel with or without
35-ngml 1 bFGF in the presence of various conditioned medias.
Plates were incubated at 37 1C and tube formation was measured as
described earlier (Chen et al, 2009).
Tumour xenograft. Female athymic nude mice (Nude-Foxn1nu)
were purchased from Harlan Sprague Dawley Inc. (Dublin, VA,
USA) and were maintained in VCU institutional animal facility in
accordance with the American Association for Laboratory Animal
Science (AALAS) guidelines. The Institutional Animal Care and
Use Committee (IACUC) of VCU approved the experiments
described in this article. Mice were allowed free access to standard
laboratory rodent food and water. The mice used for the
experiment were between 8–12 weeks of age and B20 g body-
weight. Subcutaneous xenografts were established in the flanks of
athymic nude mice using HT29 (1 107) cells. When tumours
reached a volume of 100mm3, mice were randomised and divided
into four groups of five-mice per group. These four groups of
animals were treated as follows: (i) Ad.5/3-vec (1 108 pfu);
(ii) Ad.5/3-mda-7 (1 108 pfu); (iii) BI-69A11 (15mg per kg
body-weight); (iv) Ad.5/3-mda-7þBI-69A11. The adenoviruses
(total nine injections in 3 weeks) and BI-69A11 (3 times per week)
were administered as intratumoural and intraperitoneal injections,
respectively. Tumour volume was measured twice weekly by
calipers, using the equation: (A) (B2) p/6, where A was the length
of the longest aspect of the tumour, and B was the length of the
tumour perpendicular to A (Dash et al, 2011).
Immunohistochemistry. For immunohistochemical analysis,
tumour specimens were fixed in formalin and embedded in
paraffin and sectioned. Immunostaining was performed as
described previously with different antibodies including anti–p-
Akt (Ser473), anti–Akt, anti–Ki-67, and anti–CD31, anti–p-
ribosomal-S6 protein and anti–ribosomal-S6. TUNEL Assay was
carried out in the tissue as per manufacturer’s protocol.
RESULTS
BI-69A11 inhibits in vitro cell proliferation in a dose- and time-
dependent manner in multiple colon cancer cell lines. The
ability of BI-69A11 to inhibit cell proliferation of HT29, HCT15,
HCT116 and SW480 CRC cells was determined by MTT assay
(Figure 1A). The IC50 values for HT29, HCT15, HCT116 and
SW480 are 8.083±0.332, 2.074±0.102, 5.360±0.144 and
9.896±0.995, respectively for 12 h, and 5.172±0.063,
1.838±0.118, 3.393±0.069 and 2.635±0.420, respectively for
24 h, and 2.540±0.154, 1.485±0.125, 1.973±0.111, 2.255±0.353,
respectively for 48 h. Live dead assays also reflected a decrease in
the number of viable cells in a time-dependent manner in both
HT29 and HCT116 cells following treatment with the IC50 of
BI-69A11 (Figure 1B and Supplementary Figure S2).
To study the chronology of the cellular and molecular events
occurring after BI-69A11 treatment, cell cycle analysis using flow
cytometry was performed (Figure 1C; Supplementary Figure S1).
This experiment indicated a substantial accumulation in sub
G0/G1 of both cell lines during different time intervals. In the case
of HCT116 cells, BI-69A11 treatment produced a substantial
increase in sub G0/G1 cells (47.1%) compared with the control
(2.4%). Similarly, for HT29 cells, BI-69A11 caused a 52.7%
accumulation of cells in the sub G0/G1 phase vs 1.03% in control
(Figure 1C and Supplementary Figure S1). These data indicate that
BI-69A11 induces apoptosis in CRC cells.
BI-69A11 induces apoptosis in CRC cells. The possibility that
growth inhibition of BI-69A11 was owing to induction of apoptosis
was further suggested by DAPI staining (Figure 2). Treatment with
DMSO did not appreciably induce apoptosis, but typical
morphological changes associated with apoptosis, including cell
shrinkage, apoptosome formation and DNA fragmentations were
observed in BI-69A11-treated HT29 and HCT116 cells
(Figure 2A). TUNEL assays further documented these apoptotic
events. The increase in TUNEL-positive cells (green cells) was
observed in BI-69A11-treated HT29 and HCT116 cells (Figure 2B;
Supplementary Figure S3).
Activation of pro-caspase-3 is a critical mediator of apoptosis
resulting in proteolytic cleavage of the nuclear enzyme PARP. A
decrease in the level of pro-caspase-3 along with an increase in
cleaved PARP was observed in HT29 and HCT116 cells
(Figure 2C). Induction of Bcl-2 promoter activity by IGF-1 occurs
via a PKB/Akt pathway involving the cyclic AMP-response
element binding protein transcription factor. Therefore, we
checked the expression of BAX, a pro-apoptotic protein that is
regulated through a Bcl-2 mediated pathway. The level of BAX as
well as AIF (another pro-apoptotic protein) was increased in a
time-dependent manner (Figure 2C). Moreover, a decrease in the
level of XIAP was observed that also occurred in an Akt-dependent
manner as reported earlier (Dan et al, 2004). Flow cytometry assays
with Annexin-V-FITC/PI provided further confirmation that the
numbers of apoptotic cells, i.e., Annexin-V-FITCþ apoptotic cells,
were increased in a time-dependent manner in the treated groups
(Figure 2D), which was consistent with the earlier described results
obtained through MTT growth assays as well as live dead cell
assays.
Effect of BI-69A11 and mda-7/IL-24 on colon cancer BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2014.227 103
Effect of BI-69A11 on phosphorylation of Akt and its down-
stream targets in cancer cells. Akt is activated owing to
phosphorylation at Ser473 and Thr308 sites in the regulatory
and activation loop of Akt kinase. Experiments showed that BI-
69A11 downregulated IGF-mediated phosphorylation of Ser473-
Akt and Thr308-Akt without affecting the total amount of Akt
(Figure 3A). In addition, a significant decrease in IGF-induced
phosphorylation at both Ser473 and Thr308 residue in the case
of HCT116 and HT29 cells was evident after BI-69A11
treatment (Figure 3B). However, the decrease in level of
phosphorylation of Ser473 and Thr308 was almost similar in
HCT116 cells, whereas the decrease in the level of phosphoryla-
tion of Thr308 was more pronounced than Ser473 in the case of
HT29 cells. To determine the effect of BI-69A11 on Akt kinase
activity, cells were treated with BI-69A11 and kinase activity was
evaluated. The results obtained in this experiment were
compared with another Akt inhibitor GSK690693, used as a
positive control. Figure 3C confirms a decrease in Akt kinase
activity in BI-69A11-treated HCT116 cells compared with
the control. Histogram analysis (Figure 3D) showed that
the inhibition by BI-69A11 was almost equal to that of the
GSK690693-treated sample. However in the case of HT29,
the inhibitory effect of BI-69A11 was significantly less compared
with the inhibition in HCT116. As inhibition of Akt could
further affect its substrate phosphorylation, the effect of
BI-69A11 on the downstream targets of Akt including
IGF-mediated phosphorylation was analysed by Western blot-
ting. Figure 3E demonstrated that BI-69A11 treatment induced
down-regulation of IGF-mediated phosphorylation of GSK-3b,
ribosomal-S6 and 4E-BP1without affecting the total level of
GSK-3b, ribosomal-S6 and 4E-BP1.
BI-69A11 inhibits cell migration and invasion capabilities of
CRC cells. To study the inhibitory effect of BI-69A11 on cell
migration, wound-healing assays were performed. At 48 h, the
wound was decreased in control cells, but still remained relatively
larger in treated samples in both HCT116 and HT29 cultures
(Figure 4A). However, less closure of the wound was observed in
HT29 cells in control samples (Figure 4A). Boyden chamber assays
were used to determine the effect of BI-69A11 on the invasion
potential of HT29 cells. Treatment with BI-69A11 induced a
significant 48% reduction (P¼ 0.0008) in invasion of the treated
cells compared with the control cells (Figure 4C).
BI-69A11 enhances Ad.5/3-mda-7-induced growth inhibition.
We also evaluated the combinatorial effect of BI-69A11 and
mda-7/IL-24 on colorectal cancer cell growth. Previous studies
suggest that a sub-lethal dose of Ad.5/3-vec or Ad.5/3-mda-7 of 25
pfu per cell for HCT116 and 100 pfu per cell for HT29 cells caused
no substantial or a minimal decrease in cell viability in these colon
cancer lines (Lebedeva et al, 2007). Earlier reports also suggested
that Ad.5/3-mda-7 alone showed limited effect on growth
inhibition of two colon cancer cell lines (Lebedeva et al, 2007).
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Figure 1. Anti-proliferative effect of BI-69A11 on colon cancer cells. (A) Dose-dependent growth inhibitory effects of BI-69A11 on colorectal
cancer cell lines. HCT116, HT29, HCT15 and SW480 cells were treated with various concentrations of BI-69A11 and incubated for 12, 24 and 48h,
respectively, and MTT assays were performed. Points, average±s.d. of three different experiments each performed in triplicate, Po0.05. (B) The
indicated cells were treated with an IC50 dose of BI-69A11 for indicated time (hrs). Cells were stained with calcein AM and ethidium bromide and
images were captured. Graphical representations of live and dead cells in the experiment are shown as histograms; *Po0.05, **Po0.01,
***Po0.001 represents level of significance with respect to control. (C) Cell cycle analysis was performed by treating the indicated cells with an
IC50 dose of BI-69A11. Cells were exposed to the indicated concentrations of BI-69A11 for 3, 6, 12 and 24 h followed by propidium iodide
staining. The data represent the percentage accumulation of cells in each phase and are representative of three independent experiments.
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We hypothesised that a combinatorial approach of Ad.5/3-mda-7
(Dash et al, 2010) and BI-69A11 might be useful in augmenting
growth suppression and apoptosis. Following treatment with
different doses of BI-69A11 (0.1–5 mM) in combination with
Ad.5/3-mda-7 (25 pfu per cell for both HCT116 and HT29), we
observed a significant decrease (Po0.01) of cell viability in both
the cell lines (Figure 5A). We also observed that the combination of
Ad.5/3-mda-7 resulted in a decrease of the IC50 value of BI-69A11
in both cell lines. The IC50 value of combinatorial treatment in
HT29 and HCT116 was 0.644±0.065 and 1.170±0.107, respec-
tively, as compared with IC50 value of BI-69 in HT29 and HCT116
of 2.540±0.154 and 1.973±0.111, respectively, after 48 h
(Figure 5A).
BI-69A11 enhances Ad.5/3-mda-7-induced growth inhibition by
blocking Akt. Further analysis suggested that the combination of
BI-69A11 and Ad.5/3-mda-7 increased cleaved caspase-3 and
cleaved PARP levels more than BI-69A11 or Ad.5/3-mda-7 alone
(Figure 5B). Moreover, we observed an appreciable increase in the
expression level of the apoptosis-inducing protein BAX and a
concomitant decrease in the expression of the anti-apoptotic XIAP
protein (Figure 5B) following combinatorial treatment with
BI-69A11 and Ad.5/3-mda-7.
BI-69A11 inhibited Akt phosphorylation and Akt kinase activity
in HCT116 and HT29 cells (Figure 3). We therefore investigated
whether the combinatorial effect of BI-69A11 and Ad.5/3-mda-7
also promoted growth inhibition in an Akt-dependent manner. A
significant reduction in p-Akt expression level and its downstream
target p-S6 was observed following combinatorial treatment with
BI-69A11 and Ad.5/3-mda-7 compared with cells treated with
either agent alone (Figure 5B). However, no change in the total Akt
level was observed.
The combination of Ad.5/3-mda-7 and BI-69A11 inhibits cell
invasion and angiogenesis. To assess the in vivo anti-angiogenic
effect of Ad.5/3-mda-7 and BI-69A11, alone and in combination,
we used the CAM model. The angiogenic protein vascular
endothelial growth factor (VEGF) promoted new blood vessel
and capillary growth compared with Ad.5/3-vec-treated control
(Figure 6). In contrast, inhibition of new blood vessel formation
leading to a vascular zone was observed in Ad.5/3-mda-7,
BI-69A11 and combination-treated samples (Figure 6A). As
quantified in Figure 6B, it is evident that the extent of inhibition
of angiogenesis is relatively higher in the combination-treated
sample and the combination treatment also has the potential to
vinhibit VEGF-induced angiogenesis as studied by CAM assay.
Figure 6B shows that the number of microvessels formed was
significantly less in the combined-treated sample (P¼ 0.0016)
compared with Ad.5/3-vec. A significant decrease in microvessels
formation is also observed in individual drug-treated samples
compared with Ad.5/3-vec (P¼ 0.0479). However, the decrease in
Ad.5/3-mda-7 compared with Ad.5/3-vec is insignificant
(P¼ 0.1582). Moreover, the decrease in microvessel formation is
more significant in combined-treated samples as compared with
individual drug-treated samples (P¼ 0.0034).
To investigate further the in vitro anti-angiogenic effect of the
combination of Ad.5/3-mda-7 and BI-69A11, capillary formation
assays were performed. In the presence of VEGF, formation of
elongated and robust tube-like structures, much larger than the
controls, were observed. However, treated samples showed a
different trend corresponding to abrogation of the width and the
length of endothelial tubes (Figure 6C). The decrease in the length
and width of the capillaries was more pronounced in Ad.5/3-
mda-7 plus BI-69A11-treated cells as compared with the cells
treated individually. Also the VEGF-induced Ad.5/3-mda-7 plus
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Figure 2. BI-69A11 induces apoptosis of colon cancer cells. (A) Characteristic apoptotic cells were detected in HCT116 and HT29 cell lines treated
with BI-69A11 for 12 and 24h by staining with DAPI. Photographs were taken under 20 magnifications using a confocal microscope. (B) TUNEL
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photographs were taken at 20 magnification and are representative of three separate experiments. (C) Western blotting of HCT116 and HT29
cells treated with BI-69A11 for the indicated times. Representative figures of three independent experiments. (D) Apoptosis was determined by
flow-cytometric detection of Annexin V-FITC-positive cells treated for the indicated hours with BI-69A11. Representative histograms from three
independent experiments are shown. The relative number of cells in each quadrant is given in per cent. **Po0.01, ***Po0.001 represents level of
significance with respect to control.
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BI-69A11-treated samples displayed a similar response. These
findings demonstrate a substantial impact of the combinatorial
treatment with Ad.5/3-mda-7 and BI-69A11 on blocking
angiogenesis. The extent of cumulative tube formation was
significantly decreased in the combined-treated sample
(P¼ 0.0012) as compared with the Ad.5/3-vec. A significant
decrease was also observed in individual drug-treated samples
(P¼ 0.0129) as compared with the Ad.5/3-vec (Figure 6D).
However, the decrease in tube formation was more significant in
combined-treated samples as compared with individual drug-
treated samples (P¼ 0.0013).
Boyden chamber assays were performed to determine the effect
of the combination on cell invasion. In the Ad.5/3-vec-treated
group, a large number of HT29 cells migrated from the lower
chamber to the upper chamber owing to its high-invasive nature
(Figure 7A). The rate of invasion was decreased in the individual-
treated cells and was reduced to the greatest extent in the
combination-treated group. Figure 7B provides the quantified data
on the rate of invasion, which indicates the synergistic effect of the
combination in comparison with the individual drug-treated or
Ad.5/3-mda-7-infected samples.
The combination of Ad.5/3-mda-7 and BI-69A11 inhibits
tumour growth in vivo. To evaluate the efficacy of the Ad.5/3-
mda-7 plus BI-69A11 treatment in vivo on human CRC cells, we
employed a nude mouse HT29 xenograft model. In the Ad.5/3-vec
group, the mean tumour volume was 1383.3±143.4 after day 25.
On the other hand, in BI-69A11, Ad.5/3-mda-7 and the Ad.5/3-
mda-7 plus BI-69A11-treated groups; mean tumour volumes after
25 days were 187.3±156.9, 364.5±174.6 and 86.2±34.3, respec-
tively (Figure 8A). Thus, a significant decrease in the tumour
volume was observed in the Ad.5/3-mda-7 plus BI-69A11-treated
groups (P¼ 0.0054) compared with Ad.5/3-vec-treated group. A
less significant trend is observed in the individual drug- or Ad.5/3-
mda-7-treated groups’ compared with Ad.5/3-vec-treated group
(P¼ 0.0249 and 0.0876, respectively). However, the decrease in
tumour volume in combined-treated group is more significant
compared with individual drug-treated groups (P¼ 0.010). A
similar trend was observed in the case of tumour mass (Figure 8B).
The mean tumour mass of the control group was 0.975±0.154,
whereas the mean tumour mass of the BI-69A11, Ad.5/3-mda-7
and Ad.5/3-mda-7 plus BI-69A11-treated groups after 25 days
were 0.404±0.074, 0.674±0.057 and 0.174±0.066, respectively.
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Here also a marked decrease in the tumour mass was observed in
the case of the combined-treated than the individual drug- or Ad.5/
3-mda-7-treated group. In addition to these observations, a marked
decrease in Ki-67 and CD31 expression correlated well with the
reduced rate of proliferation and angiogenesis observed in the
groups receiving Ad.5/3-mda-7 plus BI-69A11 (Figure 8C).
Supplementary Figure S4 also depicts the significant decrease in
Ki-67 and CD31 expression levels observed in the combination-
treated samples vs the individual-treated samples (Po0.05).
To determine whether the combinatorial effect of Ad.5/3-mda-7
and BI-69A11 induced apoptosis in vivo, TUNEL assay was done.
Mice receiving the Ad.5/3-mda-7 plus BI-69A11 treatment had an
increased number of TUNEL-positive cells compared with the
groups treated with a single agent (Figure 8C). Next, we
determined the effect of combinatorial treatment on the Akt
signalling pathway in the in vivo-derived tumour samples.
Immunohistochemistry analysis demonstrated decreased levels
of p-Akt and p-S6 expression in tumours treated with
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Ad.5/3-mda-7 plus BI-69A11 (Figure 8C). No changes in total Akt
and S6 levels were observed. Supplementary Figure S4 provides
diagrammatic data indicating that p-Akt and p-S6 expression
levels are significantly decreased in combination-treated samples
(Po0.05).
DISCUSSION
The present study evaluated the activities in human CRC cells of
BI-69A11, a competitive and potent inhibitor of Akt that was
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synthesised based on the reported crystal structure of AKT1
kinase and identified by using a virtual docking approach based
on consensus scoring (Forino et al, 2005). Earlier reports
suggested that competitive inhibition of Akt would result in the
effective inhibition of growth of melanoma cells in vitro and
in vivo in animal models (Gaitonde et al, 2009). PIK3CA
mutation has been found in 32% of colon cancers and leads to the
hyperactivation of the Akt pathway. Moreover, constitutively
active AKT1 has a key role in the biology of CRC, with multiple
factors associated with Akt activation. In this study, we report
that BI-69A11 exerts anti-proliferative effect by inhibiting Akt
phosphorylation and kinase activity. Additional studies indicate
that BI-69A11 decreases cell viability mainly by triggering
apoptosis, as evident by an increase in sub G0/G1 population of
cells, characteristic morphological changes of apoptosis in the
nucleus, cleavage of PARP and increase in BAX as well as an
increase in TUNEL-positive cells in HCT116 and HT29 cells.
HCT116 contains a PIK3CA mutation and a mutant K-ras gene
and HT29 cells contain PIK3CA mutation, a B-Raf mutation and
a wild type K-ras gene. However the IC50 value is higher in HT29
cells, which might raise concern. Further results confirm that
BI-69A11 inhibits Akt phosphorylation and Akt kinase activity.
The decrease in kinase activity is relatively low in HT29 cells
compared with HCT116 cells. The ability of Akt to phosphorylate
its downstream targets including GSK-3b, ribosomal-S6 protein
and 4E-BP1 was markedly decreased in the presence of BI-69A11.
BI-69A11 can suppress wound healing, angiogenesis (CAM
assay), tumour cell invasion (Boyden chamber assay) and
tumourigenesis in vivo in an animal model indicating multiple
targets for inhibiting cancer phenotypes that are regulated by Akt
pathway activation. In conclusion, BI-69A11 inhibits the down-
stream targets of Akt irrespective of substrate specificity.
Owing to the multiple signalling pathway alterations in human
cancers that lead to chemotherapeutic resistance, inhibition of one
target molecule/pathway may be insufficient because other
components can compensate for the inhibited targeted molecule.
It is accepted that combining Akt inhibitors with other cancer
therapeutics is a promising way to improve cancer therapy. MK-
2206 in combination with other chemotherapeutic drugs including
carboplatin, gemcitabine, 5FU and doxorubicin produce better
antitumour effects than a monotherapy (Hirai et al, 2010). These
combinations also have more profound effects on cancer cell lines
expressing wild type K-ras than those expressing mutant K-ras
(Gulhati et al, 2012). The second best-characterised RAS effector
family molecules are PI3Ks, which play important roles, as
mediators of RAS-driven cell survival and proliferation
(Castellano and Downward, 2010). Melanoma differentiation
associated gene-7/interleukin-24 functions as an efficient anti-
tumour and apoptosis-inducing gene in diverse cancer cells in vitro
and in vivo but its efficacy is attenuated to some degree in specific
colorectal cancer cells. This could be owing to frequent K-ras
mutations in CRCs that might impact on the ability of mda-7/IL-
24 to induce apoptosis (Bos et al, 1987). Previous reports suggest
that a sub-lethal dose of Ad.5/3-mda-7 results in a minimal
decrease in cell viability of HT29 (wild type K-ras) and HCT116
cells (mutant K-ras) (Lebedeva et al, 2007). As K-RAS acts through
the PI3K–Akt-mediated pathway, we hypothesised that combining
an Akt inhibitor with mda-7/IL-24 could enhance the antitumour
effect of Ad.5/3-mda-7. Currently, we show that combined
treatment with sub-lethal doses of both Ad.5/3-mda-7 and
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magnification 20 .
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BI-69A11 increase growth inhibition in both cell lines which was
more pronounced in HT29 as compared with HCT116 cells.
The strategy that we employed involving a combination of
Ad.5/3-mda-7 gene therapy with BI-69A11 efficiently enhanced
antitumour effects against colon cancer cells. The growth
inhibitory effects of this combination involved inhibition of
the Akt pathway and were affected by K-ras mutation. This was
further confirmed with increased cleavage of PARP, cleavage of
caspase-3 and upregulation of BAX expression with a con-
comitant decrease in XIAP expression. These data support the
conclusion that this combination effectively induces apoptosis.
Dual targeting of phosphorylation of Akt of colon cancer
induces growth inhibition to a greater extent but with a
relatively low sub-lethal dose of both BI-69A11 and Ad.5/3-
mda-7. In the case of HT29, the decrease in the IC50 dose of BI-
69A11 is more profound in the presence of Ad.5/3-mda-7 than
in HCT116.
Akt has an important role in regulating normal vascularisation
and pathological angiogenesis (Jiang and Liu, 2008; Okumura et al,
2012). This is due to the activation of Akt, which induces VEGF
and HIF-1 expression through its two downstream molecules
HDM2 and p70S6K1 (Jiang and Liu, 2008). To evaluate the effect
of this combination on angiogenesis, CAM and HUVEC assays
were performed. In vitro and in vivo angiogenesis assays also
confirmed the fact that the combination of BI-69A11 and Ad.5/3-
mda-7 inhibits angiogenesis that might be mediated through
inhibition of p70S6K1 kinase. Boyden chamber assays also
supported the fact that the combination treatment inhibited cell
invasion. Moreover, the combinatorial treatment markedly reduced
in vivo tumour growth that was accompanied with decreased
proliferation and angiogenesis, which was owing to decreased Akt
phosphorylation. Thus, the combination treatment could be an
effective therapeutic to prevent colorectal tumour growth and
metastasis.
In summary, we presently demonstrate that targeting Akt and
its downstream signalling pathways with BI-69A11 in combination
with expression of the cancer-specific apoptosis-inducing cytokine
gene mda-7/IL-24 effectively diminishes the growth of human
colorectal cancer cells in vitro and in vivo in nude mice, with
respect to their K-ras status. BI-69A11 generally exerted minimal
cytotoxic effects on normal cell lines even at a concentration of
10 mM which is upper limit of the experimental concentration range
(0–10 mM). Combining BI-69A11 with Ad.5/3-mda-7 reduced
cytotoxicity dramatically because lower doses were required when
combining the Akt inhibitor with the therapeutic cytokine-
producing virus. Moreover, combining Ad.5/3-mda-7 with
BI-69A11 increased the therapeutic efficacy of Ad.5/3-mda-7 in
colon cancer cells displaying either a wild type or mutant K-ras.
These results suggest potential applications of this combinatorial
approach for the therapy of colorectal cancer.
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